Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis - an observational cohort study

Table 3 Crude incidence rates of first episodes of Human papillomavirus-related cancers among persons with end-stage renal disease and population controls during 1994-2010

Anatomical region	Group	No.	Risk time^a	Crude IR^b(95% CI)	IRR (95% CI)	P value
Head and neck^c	ESRD	18	0.608	29.6 (18.6-47.0)	1.77 (1.10-2.84)	0.02
Head and neck^c	Controls	328	19.559	16.8 (15.1-18.7)	1.77 (1.10-2.84)	0.02
Cervical^d	ESRD	12	0.229	52.3 (29.7-92.1)	1.81 (1.01-3.23)	0.05
Cervical^d	Controls	221	7.644	28.9 (25.3-33.0)	1.81 (1.01-3.23)	0.05
Vulva and vagina^d	ESRD	15	0.229	65.4 (39.4-108)	5.81 (3.36-10.1)	<0.001
Vulva and vagina^d	Controls	86	7.644	11.3 (9.11-13.9)	5.81 (3.36-10.1)	<0.001
Penis^e	ESRD	5	0.379	13.2 (5.49-31.7)	2.02 (0.82-4.98)	0.1
Penis^e	Controls	78	11.915	6.55 (5.24-8.17)	2.02 (0.82-4.98)	0.1
Anal	ESRD	12	0.608	19.7 (11.2-34.7)	4.54 (2.48-8.31)	<0.001
Anal	Controls	85	19.559	4.35 (3.51-5.38)	4.54 (2.48-8.31)	<0.001
All HPV-related	ESRD	62	0.608	102 (79.5-131)	2.50 (1.93-3.24)	<0.001
	Controls	798	19.559	40.8 (38.1-43.7)

Abbreviations: HPV Human papilloma virus, No. number of HPV-related cancers, CI confidence interval, IR incidence rate, IRR incidence rate ratio, ESRD end-stage renal disease.
^a 100,000 years.
^b Per 100,000 person-years.
^c HPV-related head and neck cancer sites as outlined in Table 1.
^d Only females contributed to risk time.
^e Only men contributed to risk time.

ISSN: 1471-2369